Bristol Myers Squibb (BMY) announced data from the cohorts of the KRYSTAL-1 study, evaluating the lung cancer drug Krazati (adagrasib) in combination with Erbitux (cetuximab), for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC).KRYSTAL-1 is an open-label, multicenter, multiple expansion cohort phase I/II study to determine the safety and efficacy of Krazati in patients with advanced solid tumors that harbor a KRASG12C mutation.The pri ...